2/22/2006

Golden exclusivity

Filed under: — Licenblog @ 9:36 am on


After Japan, the Pravastatin - the revolutionary drug for hyperlididemia is moving to the generic realm in US as well.

Licenblog is a joint blog - post or send comments to licenblog@licenscape.com

Comments (0)

2/17/2006

The end of Pravastatin age

Filed under: — Licenblog @ 9:38 am on


The following enigmatic announcement has been posted at the web site of Daiichi Sankyo on February 17, 2006. Neither BMS nor Watson has any references for the announcement.

Future Business Prospects of the Hyperlipidemia Drug Pravastatin in the United States

Tokyo, February 17, 2006 - DAIICHI SANKYO COMPANY, LIMITED has announced today that the exclusive sales period for the hyperlipidemia drug Pravachol® (Japanese brand name: Mevalotin®), that is supplied by its subsidiary Sankyo Co., Ltd. (President: Yasuhiro Ikegami; hereafter Sankyo) to Bristol-Myers Squibb Company (hereafter BMS), in the United States is coming to an end as of April 20, 2006, and an agreement has been reached between BMS and Watson Pharmaceuticals, Inc. for the sale of generic versions of Pravachol® within the United States. Sankyo is supplying the active constituent for pravastatin to BMS, which is in turn selling it in the United States and throughout the world. Sankyo will continue to supply the active constituent of pravastatin through BMS.

Licenblog is a joint blog - post or send comments to licenblog@licenscape.com

Comments (0)

2/15/2006

Privacy hurts

Filed under: — Licenblog @ 9:41 am on

A new, although not unexpected findings were summarized in the article posted at the web site of The Daily Yomiuri (with omissions):

Surveys feel pinch of privacy / Information protection law making public opinion hard to tap


…In October, a panel of the Internal Affairs and Communications Ministry decided to allow Basic Resident Register information to be used for academic research, while proposing prohibiting access for business purposes. Surveys ordered by the central government and other public entities have faced similar problems. Before the law’s enactment, response rates for surveys by public entities were about 10 points higher than those of surveys conducted by private companies. But since spring, when the law came into effect, the response rates of the public surveys began falling remarkably. The rates are now close to those of private company surveys. ..Survey workers were often turned away at the door before explaining the purposes of the survey in many cases. When the center asked survey workers for the reasons people refused to respond in November, many replied that the visits themselves were disliked, and the workers were thought to be pushing business scams. Partly because of malevolent home-visit sales and ‘It’s me’ frauds, people tend to link proper surveys with swindling. (Feb. 15, 2006)

Licenblog is a joint blog - post or send comments to licenblog@licenscape.com

Comments (0)